Navigation Links
Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
Date:2/14/2011

PRINCETON, N.J., Feb. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Leerink Swann Hot Topics Roundtable Conference being held February 16 - 17, 2011 at the Roosevelt Hotel, New York, NY. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide a review of the Company's HCV drug pipeline at the conference at 1:30 PM (ET) and Dr. Michelle Berrey, Pharmasset's Chief Medical Officer will be participating in an HCV panel discussion at 4:10 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast. A replay of the webcast will be available on Pharmasset's website for thirty days following the conference.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
2. Pharmasset Announces Exercise of Underwriters Overallotment Option
3. Pharmasset Prices Public Offering of Common Stock
4. Pharmasset Announces Proposed Public Offering of Common Stock
5. Pharmasset Reports Positive Results from its HCV Clinical Programs
6. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
8. Pharmasset to Webcast an Investor Event from the AASLD Meeting
9. Pharmasset to Present at the JMP Healthcare Conference
10. Pharmasset to Present at the UBS Global Life Sciences Conference
11. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... PALO ALTO, Calif., July 23, 2014  Varian Medical ... net earnings of $1.02 per diluted share in the ... negatively impacted by about $0.06 per diluted share due ... a portion of Varian,s existing equity investment in Augmenix, ... Varian,s company-wide revenues totaled $748 million for the third ...
(Date:7/23/2014)... N.Y. , July 23, 2014 The ... VSCP ), a leading provider of clinical trial imaging ... 48, has been named president and chief executive officer, ... Directors in August 2013 and has held the positions ... 25, 2013. Dr. Charles E. Phelps ...
(Date:7/23/2014)... and MOUNTAIN VIEW, Calif. , July ... leader in translational preclinical research, today unveiled their new ... signaling the transformation of Surpass, corporate culture to one ... our customers. This press release comes on the heels ... were added to the Silicon Valley Team:  David Craig, ...
Breaking Medicine Technology:Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... 7, 2011 The U.S. Food and Drug Administration ... treat patients with late-stage (metastatic) head and neck cancer. ... Combined with chemotherapy, Erbitux extended the lives of ... chemotherapy alone. Erbitux already is FDA-approved for certain types ...
... Psychemedics Corporation, hair testing for drugs of ... announced today that its laboratory has received international ... of laboratory testing including drugs of abuse ... The International Organization for Standardization/International Electrotechnical Commission ...
Cached Medicine Technology:FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer 2FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer 3Psychemedics Awarded ISO/IEC 17025 International Accreditation 2Psychemedics Awarded ISO/IEC 17025 International Accreditation 3
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
(Date:7/23/2014)... ( FXS ) is a genetic disorder that causes ... autistic spectrum, as well as cognitive deficits. It is ... the most common cause of autism. , Now biomedical ... a study that sheds light on the ... (July 23) in the Journal of Neuroscience , ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad ... Friday, July 18. Hedrick visited Roanoke as the special ... an Olympic-style event celebrating its 25th Anniversary in 2014. ... premier sponsor of the Commonwealth Games, which like Foot ... and all activity levels. , Hedrick, a native of ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, 2014 (HealthDay ... may be determined by hundreds, and possibly thousands, of gene ... over 100 regions of DNA that are connected to the ... researchers hope these findings will shed light on the biology ... to breast cancer. "These findings will provide additional insights ...
(Date:7/23/2014)... TX (PRWEB) July 23, 2014 Texas ... seven physical therapists from their Westlake, Westgate, Liberty Hill, ... earned the professional designation of Orthopaedic Certified Specialist ... this June. Adriana Juarez, PT, DPT, OCS, Tony Lauretta, ... Milligan, PT, DPT, OCS, Joseph Leech, PT, DPT, OCS, ...
Breaking Medicine News(10 mins):Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3
... BIRMINGHAM, Ala. - New clinical data showed some cancer ... called AME-133v, said a researcher at the University of ... April 15th during the 2008 annual meeting of the ... Phase 1 clinical trial data showed AME-133v had a ...
... YORK, April 16 Jenni Schaefer, a young,woman ... with anorexia and,bulimia to become a well-known motivational ... girls everywhere, has been,appointed to the Ambassador Council ... a NEDA Ambassador, Schaefer will continue her travels ...
... April 16 Natural,Nutrition, Inc. (OTC Bulletin ... InterACTIVE Nutrition, Inc. (INII), http://www.interactivenutrition.com, achieved ... in EBITDA in the three month period ... exceeded the EBITDA requirements,for the company,s senior ...
... New NCPA,Study, DALLAS, April 16 The U.S. ... workers when they work,extra hours to get ahead, according ... Policy Analysis., "The impact on low-income workers and ... Kotlikoff, Boston University,professor and author of the study. "They ...
... are doomed to fail , , WEDNESDAY, April 16 (HealthDay ... household dust? Forget about it, a new study suggests. ... found that none was effective enough in reducing exposure ... The methods looked at included using chemicals to kill ...
... SAN DIEGO As potential cancer therapies proliferate, researchers ... to more accurately predict which patients will receive the ... Research 2008 Annual Meeting, April 12-16, 2008, researchers present ... cancer, how doctors can more effectively measure response to ...
Cached Medicine News:Health News:Jenni Schaefer, Motivational Speaker, Author Named National Eating Disorders Association (NEDA) Ambassador 2Health News:Natural Nutrition Subsidiary InterACTIVE Nutrition Reports First Quarter Revenue of $4,189,048 (CDN) and EBITDA of $504,500 (CDN) 2Health News:Tax Rates Mean Extra Work Doesn't Pay 2Health News:Dust Mites Trump Asthma Prevention Guidelines 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 3Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 4Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 5Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 6
... Enhanced features including aspiration holes and ... laparoscopic procedures requiring precise dissection with ... increased suction demands. ,Flexible design ... and nonretractable electrodes and multiple tip ...
... including aspiration holes and additional electrode ... requiring precise dissection with decreased risk ... demands. ,Flexible design options allow ... electrodes and multiple tip designs. Optimize ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: